8 nouveaux projets soutenus par le PSCC

Nous sommes ravis d'annoncer que 5 nouveaux projets ont été sélectionnés par le PSCC pour bénéficier de son soutien :

(détails en anglais ci dessous)

Carla Biotherapeutics :

A preclinical stage biotech developing a pipeline of precision immunotherapies for severe and aggressive diseases based on a fully integrated adaptive CAR-T platform plug-and-play technology.

Hippoxis

A start-up develops an oral drug HPX-612  targeting intestinal innate immunity and treat metastatic and agressive pediatric cancers.

Inatherys

A clinical stage biotech developing an ADC targeting transferrin receptor and coupled to MMAE, with first clincal phase in hematological cancers

Neolys Diagnostics :

Diagnostic company which offers simple and effective blood biological tests to evaluate individual radiosensitivity to optimize radiotherapy treatment and thus improve the quality of life of patients.

Rainpath:

Rainpath uses AI to virtually "stain" biopsy images , helping doctors see tissue details more clearly and make faster, more accurate diagnoses without traditional lab processing.

Seekyo Therapeutics :

Shifting to a new paradigm, Seekyo, a preclinical stage biotech, offers a breakthrough approach for solid tumors in targeting specific functional proteins within the Tumor Micro-Environment :  Tumor Activated TherapyTM

Starkage Therapeutics 

Start-up proposing therapies that eliminate senescent cells induced by standard cancer treatments.

And an 8th project to be announced soon

With 70+ cutting-edge oncology projects selected and supported, the PSCC offers the most promising projects to a comprehensive array of resources: expertise, networking, financing, data, samples, technologies, infrastructures, training, laboratories.

Do you develop an innovative solution for patients in oncology ? Learn more about how to apply to the PSCC : https://www.parissaclaycancercluster.org/en/postulez